Erratum: Islet G protein-coupled receptors as potential targets for treatment of type 2 diabetes (Nature Reviews Drug Discovery (2009) vol. 8 (369-385) 10.1038/nrd2782);Islet G protein-coupled receptors as potential targets for treatment of type 2 diabetes

Nature Reviews Drug Discovery

Volumn 8, Issue 5, 2009, Pages 369-385

  Ahrén, Bo ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC RECEPTOR; ALBIGLUTIDE; ALOGLIPTIN; ANTIDIABETIC AGENT; AR 231453; AVE 0010; CHOLECYSTOKININ RECEPTOR; CJC 1134; CJC 1143; DERIGLIDOLE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; G PROTEIN COUPLED RECEPTOR; GHRELIN; GLITAZONE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCAGON RECEPTOR; GW 9508; LIRAGLUTIDE; MELATONIN RECEPTOR; METFORMIN; MUSCARINIC RECEPTOR; NNC 25 0926; PURINERGIC RECEPTOR; R 1583; RIMONABANT; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA; TASPOGLUTIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VILDAGLIPTIN;

ADD ON THERAPY; CLINICAL TRIAL; DOSAGE SCHEDULE COMPARISON; DRUG ABSORPTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG EXPOSURE; DRUG HALF LIFE; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; DRUG TOLERABILITY; HUMAN; HYPOGLYCEMIA; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION;

EID: 67349176115     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd2921-c1     Document Type: Erratum

References (236)

1. Stein, C. J. & Colditz, G. A. The epidemic of obesity. J. Clin. Endocrinol. Metab. 89, 2522-2525 (2004).
2. Wild, S. et al. Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care 27, 1047-1053 (2004).
3. Fonseca, V. Clinical significance of targeting postprandial and fasting hyperglycemia in managing type 2 diabetes mellitus. Curr. Med. Res. Opin. 19, 635-641 (2003).
4. Inzucchi, S. Oral antihyperglycemic therapy for type 2 diabetes: scientific review. J. Amer. Med. Assoc. 287, 360-372 (2002).
5. Owens, D. R., Zinman B. & Bolli G. B. Insulins today and beyond. Lancet 358, 739-746 (2001).
6. Bailey, C. J. Drugs on the horizon for diabetes. Curr. Diabet. Rep. 5, 353-359 (2005).
7. Campbell, R. K. & White, J. R. More choices than ever before. Emerging therapies for type 2 diabetes. Diabetes Educator 34, 518-534 (2008).
8. Nathan, D. M. et al. Medical management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy. Diabetologia 52, 17-30 (2009).
9. Turner, R. C. The UK prospective diabetes study: A review. Diabetes Care 21 (Suppl. 3), C35-C38 (1998).
10. Hsia, S. H. & Davidson, M. B. Established therapies for diabetes mellitus. Curr. Med. Res. Opin. 18 (Suppl. 1), S13-S21 (2002).
11. Rendell, M. The role of sulphonylureas in the management of type 2 diabetes mellitus. Drugs 64, 1339-1358 (2004).
12. Diamany, M. & Heine, R. J. Thiazolidinediones in type 2 diabetes mellitus: Current clinical evidence. Drugs 63, 1373-1405 (2003).
13. Hussein, Z. et al. Effectiveness and side effects of thiazolidinediones for type 2 diabetes: Real-life experience from a tertiary hospital. Med. J. Aust. 181, 536-539 (2004).
14. Grey A. Skeletal consequences of thiazolidinedione therapy. Osteoporos. Int. 19, 129-137 (2008).
15. Lehy, J. L. Pathogenesis of type 2 diabetes mellitus. Arch. Med. Res. 36, 197-209 (2005).
16. Ahrén, B. & Pacini, G. Importance of quantifying insulin secretion in relation to insulin sensitivity to accurately asses β-cell function in clinical studies. Eur. J. Endocrinol. 150, 97-104 (2004).
17. Ahrén B. Type 2 diabetes, insulin secretion and β-cell mass. Curr. Mol. Med. 5, 275-286 (2005).
18. Wajchenberg, B. L. β-Cell failure in diabetes and preservation by clinical treatment. Endocr. Rev. 28, 187-218 (2007).
19. Prentki, M. & Nolan, C. J. Islet β cell failure in type 2 diabetes. J. Clin. Invest. 116, 1802-1812 (2006).
20. Dunning, B. E., Foley, J. & Ahrń, B. Alpha-cell function in health and disease: Influence of GLP1. Diabetologia 48, 1700-1713 (2005).
21. Ahrén B. Glucagon-like peptide-1 (GLP1): A gut hormone of potential interest in the treatment of diabetes. Bioessays 20, 642-651 (1998).
22. Drucker, D. J. The biology of incretin hormones. Cell Metab. 3 153-165 (2006).
23. Ahrén, B. & Schmitz, O. GLP1 receptor agonists and DPP-4 inhibitors in the treatment of type 2 diabetes. Horm. Metab. Res. 36, 867-876 (2004).
24. Ahrén, B. Emerging dipeptidyl peptidase-4 inhibitors for the treatment of diabetes. Expert Opin. Emerg. Drugs 13, 593-607 (2008).
25. Henquin, J. C. Pathways in β-cell stimulus-secretion coupling as targets for therapeutic insulin secretagogues. Diabetes 53 (Suppl. 3), S48-S58 (2004).
26. Leibiger, I. B. & Berggren, P. O. Insulin signaling in the pancreatic β-cell. Annu. Rev. Nutr. 28, 233-251 (2008).
27. Sörhede Winzell, M. & Ahrén, B. G-protein-coupled receptors and islet function - implications for treatment of type 2 diabetes. Pharmacol. Ther. 116, 437-448 (2007).
28. Kowluru, A. Regulatory roles for small G proteins in the pancreatic β-cell: Lessons from models of impaired insulin secretion. Am. J. Physiol. 285, E669-E684 (2003).
29. Farilla, L. et al. Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology 144, 5149-5158 (2003).
30. Drucker, D. J. Glucagon-like peptide-1 and the islet β-cell: augmentation of cell proliferation and inhibition of apoptosis. Endocrinology 144, 5145-5148 (2003).
31. Trümper, A. et al. Glucose-dependent insulinotropic polypeptide is a growth factor for β (INS-1) cells by pleiotropic signaling. Mol. Endocrinol. 15, 1559-1570 (2001).
32. Kolakowski, L. F. Jr. GCRDb: A G-protein-coupled receptor database. Receptors Channels 2, 1-7 (1994).
33. Lagerström, M. C. & Schiöth, H. B. Structural diversity of G protein-coupled receptors and significance for drug discovery. Nature Rev. Drug Discov. 7, 339-357 (2008).
34. Klabunde, T. & Hessler, G. Drug design strategies for targeting G-protein-coupled re ceptors. ChemBioChem 3, 928-944 (2002).
35. Doyle, M. E. & Egan, J. M. Mechanisms of action of glucagon-like peptide 1 in the pancreas. Pharmacol. Ther. 113, 546-593 (2007).
36. Heller, R. S., Kieffer, T. J. & Habener, J. F. Insulinotropic glucagon-like peptide I receptor expression in glucagon-producing alpha-cells of the rat endocrine pancreas. Diabetes 46, 785-791 (1997).
37. Tornehave, D. et al. Expression of the GLP1 receptor in mouse, rat, and human pancreas. J. Histochem. Cytochem. 56, 841-851 (2008).
38. Gutniak, M. et al. Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus. N. Engl. J. Med. 326, 1316-1322 (1992).
39. Holst, J. J. & Deacon, C. F. Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes. Diabetes 47, 1663-1670 (1998).
40. Ahrén, B. DPP-4 inhibitors - clinical data and clinical implications. Diabetes Care 30, 1344-1350 (2007).
41. Ahrén, B. in Best Practice & Research: Clinical Endocrinology & Metabolism (ed. Nauck, M.) (Rapid Medical Media, East Sussex, UK, in the press).
42. Ahrén, B. Exenatide: A novel treatment of type 2 diabetes. Therapy 2, 207-222 (2005).
43. Ahrén, B. GLP1-based therapy of type 2 diabetes. GLP1 mimetics and DPP-IV inhibitors. Curr. Diabetes Rep. 7, 340-347 (2007).
44. Buse, J. B. et al. Effects of exenatide (exendin-4) on glycemic con trol over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 27, 2628-2635, (2004).
45. DeFronzo, R. A. et al. Effects of exenatide (exendin-4) on glyce mic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 28, 1092-1100 (2005).
46. Kendall, D. M. et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with met formin and a sulfonylurea. Diabetes Care 28, 1083-1091 (2005).
47. Klonoff, D. C. et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr. Med. Res. Opin. 24, 275-286 (2008).
48. Pratley, R. E. & Gilbert, M. Targeting incretins in type 2 diabetes: role of GLP1 receptor agonists and DPP-4 inhibitors. Rev. Diabet. Stud. 5, 73-94 (2008).
49. Werner, U. Preclinical pharmacology of the new GLP1 receptor agonist AVE0010. Ann. Endocrinol. 69, 164-165 (2008).
50. Rosenstock, J. et al. Dose range effects of the new once daily GLP1 receptor agonist AVE0010 added to metformin in type 2 diabetes. Diabetologia 51 (Suppl. 1), S66 (2008).
51. Baggio, L. L., Huang, Q., Cao, X. & Drucker, D. J. An albumin-exendin-4 conjugate engages central and peripheral circuits regulating murine energy and glucose homeostasis. Gastroenterology 134, 1137-1147 (2008).
52. Drucker, D. J. et al. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: A randomized, open-label, non-inferiority study. Lancet 372, 1240-1250 (2008).
53. Madsen, K. et al. Structure-activity and protraction relationship of long-acting glucagon-like peptide-1 derivatives: Importance of fatty acid length, polarity, and bulkiness. J. Med. Chem. 50, 6126-6132 (2007).
54. Garber, A. et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): A randomized 52-week, phase III, double-blind, parallel-treatment trial. Lancet 373, 473-481 (2009).
55. Nauck, M. et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo- all in combination with metformin in type 2 diabetes mellitus (LEAD-2 Met). Diabetes Care 32, 84-90 (2009).
56. Marre, M. et al. Liraglutide, a once daily human GLP1 analog, added to a sulfonylurea (SU) offers significantly better glycemic control compared with rosiglitazone and SU: Combination therapy in subjects with type 2 diabetes. Diabetes 57 (Suppl. 1), A4 (2008).
57. Russell, D. et al. Significantly better glycemic control and weight reduction with liraglutide, a once daily human GLP1 analog, compared with insulin glargine: All as add-on to metformin and a sulfonylurea in type 2 diabetes. Diabetes 57 (Suppl. 1), A159 (2008).
58. Matthews, J. E. et al. Pharmacodynamics, pharmacokinetics, safety and tolerability of albiglutide, a long-acting GLP1 mimetic, in patients with type 2 diabetes. J. Clin. Endocrinol. Metab. 93, 4810-4817 (2008).
59. Berria, R. et al. 8 weeks treatment with R1583, a novel long-acting, human GLP1 analogue improves β cell function in metformin-treated diabetic subjects: A double-blind, placebo-controlled phase 2 study. Diabetologia 51 (Suppl. 1), S347-S348 (2008).
60. Ahrén, B. & Foley, J. E. The islet enhancer vildagliptin: Mechanisms of improved glucose metabolism. Int. J. Clin. Pract. 62 (Suppl. 159), 8-14 (2008).
61. Deacon, C. F. Dipeptidyl peptidase 4 inhibition with sitagliptin: A new therapy for type 2 diabetes. Exp. Opin. Investig. Drugs 16, 533-545 (2007).
62. Ahrén, B. Vildagliptin - novel pharmacological approach to treat type 2 diabetes. Therapy 5, 79-90 (2008).
63. Aschner, P. et al. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glyce mic control in patients with type 2 diabetes. Diabetes Care 29, 2632-2637 (2006).
64. Rosenstock, J. et al. Comparison of vil dagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: A 24-week, double-blind, randomized trial. Diabetes Care 30, 217-223 (2007).
65. 1c over 1 year in drug-naïve patients with type 2 diabetes. Diabet. Med. 24, 955-961 (2007).
66. Ahrén, B. et al. Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care 27, 2874-2880 (2004).
67. Goldstein, B. J. et al. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care 30, 1979-1987 (2007).
68. Bolli, G. et al. Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: A 24-week randomized, double-blind study. Diabet. Obes. Metab. 10, 82-90 (2008).
69. Garber, A. J. et al. Vildagliptin in com bination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: A randomized, placebo-con trolled study. Diabet. Obes. Metab. 9, 166-174 (2007).
70. Rosenstock, J. et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: A 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clinical Ther. 28, 1556-1568 (2006).
71. Nauck, M. A. et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: A randomized, double-blind, non-inferiority trial. Diabet. Obes. Metab. 9, 194-205 (2007).
72. Garber, A. J. et al. Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea. Diabet. Obes. Metab. 10, 1047-1056 (2008).
73. Hermansen, K. et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabet. Obes. Metab. 9, 733-745 (2007).
74. Rosenstock J. et al. Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naïve patients with type 2 diabetes. Diabet. Obes. Metab. 10, 376-386 (2008).
75. Deacon, C. F. Drug profile: Alogliptin, a potent and selective dipeptidyl peptidase-IV inhibitor for the treatment of type 2 diabetes. Curr Opin. Invest. Drugs 9, 402-413 (2008).
76. Gremlich, S. et al. Cloning, functional expression, and chromosomal localization of the human pancreatic islet glucose-dependent insulinotropic polypeptide receptor. Diabetes 44, 1202-1208 (1995).
77. Fehmann, H. C. et al. Cell and molecular biology of the incretin hormones glucagon-like peptide-1 and glucose-dependent insulin releasing polypeptide. Endocr. Rev. 16, 390-410 (1995).
78. Meier, J. J. et al. Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia. Diabetologia, 46, 798-801 (2003).
79. Vilsboll, T. et al. Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients. Diabetologia 45, 1111-1119 (2002).
80. Holst, J. J. et al. The pathogenesis of NIDDM involves a defective expression of the GIP receptor. Diabetologia 40, 984-986 (1997).
81. Younan, S. M. & Rashed, L. A. Impairment of the insulinotropic effect of gastric inhibitory polypeptide (GIP) in obese and diabetic rats is related to the downregulation of its pancreatic receptors. Gen. Physiol. Biophys. 26, 181-193 (2007).
82. Piteau, S. et al. Reversal of islet GIP receptor down-regulation and resistance to GIP by reducing hyperglycemia in the Zucker rat. Biochem. Biophys. Res. Commun. 362, 1007-1012 (2007).
83. Højberg, P. et al. Four weeks of near-normalization of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes. Diabetologia 52, 199-207 (2009).
84. Prentki, M. et al. Malonyl-CoA signaling, lipid partitioning, and glucolipotoxicity. Role in β-cell adaptation and failure in the etiology of diabetes. Diabetes 51 (Suppl. 3), 405-413 (2002).
85. Bollheimer, L. C. et al. Stimulatory short-term effects of free fatty acids on glucagon secretion at low to normal glucose concentrations. Metabolism 53, 1443-1448 (2004).
86. Corkey, B. E. et al. The role of long-chain fatty acyl-CoA esters in β-cell signal transduction. J. Nutr. 130, 299S-304S (2000).
87. Briscoe, C. P. et al. The orphan G protein-coupled receptor GPR40 is activated by medium and long chain fatty acids. J. Biol. Chem. 278, 11303-11311 (2003).
88. Itoh, Y. et al. Free fatty acids regulate insulin secretion from pancreatic β cells through GPR40. Nature 422, 173-176 (2003).
89. Kotarsky, K. et al. A human cell surface receptor activated by free fatty acids and thiazolidinedione drugs. Biochem. Biophys. Res. Commun. 301, 406-410 (2003).
90. Chu, Z. L. et al. A role for β-cell-expressed GPR119 in glycemic control by enhancing glucose-dependent in sulin release. Endocrinology 148, 2598-2600 (2007).
91. Gromada J. The free fatty acid receptor GPR40 generates excitement in pancreatic β-cells. Endocrinology 147, 672-673 (2008).
92. Overton, H. A., Fyfe, M. C. T. & Reynet, C. GPR119, a novel G-protein-coupled receptor target for the treatment of type 2 diabetes and obesity. Br. J. Pharmacol. 153, S76-S81 (2008).
93. 1R/GPR40) and its involvement in fatty-acid-stimulated insulin secretion. Cell Tissue Res. 322, 207-215 (2005).
94. Tomita, T. et al. Expression of the gene for a membrane-bound fatty acid receptor in the pancreas and islet cell tumours in humans: evidence for GPR40 expression in pancreatic β cells and implications for insulin secretion. Diabetologia 49, 962-968 (2006).
95. Brownlie, R. et al. The long-chain fatty acid receptor, GPR40, and glucolipotoxicity: Investigations using GPR40-knockout mice, Biochem. Soc. Trans. 36, 950-954 (2008).
96. Bartoov-Shifman, R. et al. Regulation of the gene encoding GPR40, a fatty acid receptor expressed selectively in pancreatic β cells. J. Biol. Chem. 282, 23561-23571 (2007).
97. Flodgren, E. et al. GPR40 is expressed in glucagon producing cells and affects glucagon secretion. Biochem. Biophys. Res. Commun. 354, 240-245 (2007).
98. + currents in primary cultured rat pancreatic β-cells by linoleic acids. Endocrinology 147, 674-682 (2006).
99. Steneberg, P. et al. The FFA receptor GPR40 links hyperinsulinemia, hepatic steatosis, and impaired glucose homeostasis in mouse. Cell Metab. 1, 245-258 (2005).
100. Latour, M. G., et al. GPR40 is necessary but not succifient for fatty acid stimulation of insulin secretion in vivo. Diabetes 56, 1087-1094 (2007).
101. Vettor, R. et al., Loss-of-function mutation of the GPR40 gene associates with abnormal stimulated insulin secretion by acting on intracellular calcium mobilization. J. Clin. Endocrinol. Metab. 93, 3541-3550 (2008).
102. Duttoray, A. et al. An improved phenotype in mice deficient in free fatty acid receptor GPR in response to a high-fat diet. Diabetes 57 (Suppl. 1), A321 (2008).
103. Zhao, Y. F., Pei, J. & Chen, C. Activation of ATP-sensitive potassium channels in rat pancreatic β-cells by linoleic acid through both intracellular metabolites and membrane receptor signaling pathway. J. Endocrinol. 198, 533-540 (2008).
104. Kebede, M. et al. The fatty-acid receptor GPR40 plays a role in insulin secretion in vivo after high-fat feeding. Diabetes 57, 2432-2437 (2008).
105. Zhang, Y. et al. The role of G protein-coupled receptor 40 in lipoapoptosis in mouse β-cell line NIT-1. J. Mol. Endocrinol. 38, 651-661 (2007).
106. Edfalk, S. et al. GPR40 is expressed in enteroendocrine cells and mediates FFA stimulation of incretin secretion. Diabetes 57, 2280-2287 (2008).
107. Bharate, S. B. et al. Discovery of diacylphloroglucinol as a new class of GPR40 (FFAR1) agonists. Bioorg. Med. Chem. Lett. 18 6357-6361 (2008).
108. Briscoe, C. P. et al. Pharmacological regulation of insulin secretion in MIN6 cells through the fatty acid receptor GPR40: identification of agonist and antagonist small molecules. Br. J. Pharmacol. 148, 619-628 (2006).
109. Tan, C. P. et al. Selective small-molecule agonists of G protein-coupled receptor 40 promote glucose dependent insulin secretion and reduce blood glucose in mice. Diabetes 57, 2211-2219 (2008).
110. Fredriksson, R. et al. Seven evolutionary conserved human rhodopsin G protein-coupled receptors lacking close relatives. FEBS Lett. 554, 381-388 (2003).
111. Overton, H. A. et al. Deorphanization of a G protein-coupled receptor for oleoylethanolamide and its use in the discovery of small-molecule hypophagic agents. Cell Metab. 3, 167-175 (2006).
112. Ueda, N. et al. N-acylphosphatidylethanolamine-hydrolyzing phospholipase D: A novel enzyme of the β-lactamase fold family releasing anandamide and other N-acylethanolamines. Life Sci. 77, 1750-1758 (2005).
113. Soga, T. et al. Lyso phosphatidylcholine enhances glucose-dependent insulin secretion via an orphan G-protein-coupled receptor. Biochem. Biophys. Res. Commun. 326, 744-751 (2005).
114. Sakamoto, Y. et al. Expression and distribution of Gpr119 in the pancreatic islets of mice and rats: Predominant localization in pancreatic polypeptide-secreting PP-cells. Biochem. Biophys. Res. Commun. 351, 474-480 (2006).
115. Chu, Z. L. et al. A role for intestinal endocrine cell-expressed G protein-coupled receptor 119 in glycemic control by enhancing glucagon-like peptide-1 and glucose-dependent insulinotropic peptide release. Endocrinology 149, 2038-2047 (2008).
116. Lauffer, L., Iakoubov, R. & Brubaker, P. L. GPR119: "Double-dipping" for better glycemic control. Endocrinology 149, 2035-2037 (2008).
117. Semple. G. et al. Discovery of the first potent and orally efficacious agonist of the orphan G-protein coupled receptor 119. J. Med. Chem. 51, 5172-5175 (2008).
118. Brown, A. J. et al. The orphan G protein-coupled receptors GPR41 and GPR43 are activated by propionate and other short chain carboxylic acids. J. Biol. Chem. 278, 11312-11319 (2003).
119. Hirasawa, A. et al. Free fatty acids regulate gut incretin glucagon-like peptide-1 secretion through GPR120. Nature Med. 11, 90-94 (2005).
120. Regard, J. B. et al. Probing cell type-specific functions of GI in vivo identifies GPCR regulators of insulin secretion. J. Clin. Invest. 117, 4034-4043 (2007).
121. Keller, M. P. et al. A gene expression network model of type 2 diabetes links cell cycle regulation in islets with diabetes susceptibility. Genome Res. 18, 707-716 (2008).
122. Tanaka, T. et al. Cloning and characterization of the rat free fatty acid receptor GPR120: in vivo effect of the natural ligand on GLP1 secretion and proliferation of pancreatic β-cells. Naunyn-Schm. Arch. Pharmacol. 377, 515-522 (2008).
123. Ahrén B. Autonomic regulation of islet hormone secretion. Implications for health and disease. Diabetologia 43, 393-410 (2000).
124. Kieffer, T. J. et al. Distribution of glucagon receptors on hormone-specific endocrine cells of rat pancreatic islets. Endocrinology 137, 5119-5125 (1996).
125. Huypens, P. et al. Glucagon receptors on human islet cells contribute to glucose competence of insulin release. Diabetologia 43, 1012-1019 (2000).
126. Gelling, R. W. et al. Lower blood glucose, hyperglucagonemia, and pancreatic alpha cell hyperplasia in glucagon receptor knockout mice. Proc. Natl Acad. Sci. USA, 100, 1438-1443 (2003).
127. Sorensen, H. et al. Glucagon receptor knockout mice display increased insulin sensitivity and im paired beta-cell function. Diabetes 55, 3463-3469 (2006).
128. Larsson, H. & Ahrén, B. Glucose intolerance is predicted by low insulin secretion and high glucagon secretion: Outcome of a prospective study in postmenopausal Caucasian women. Diabetologia 43, 194-202 (2000).
129. Ahrén B. β- and α-cell dysfunction during progression of impaired glucose tolerance. Diabetes 58, 726-731 (2009).
130. Sloop, K. W. et al. Glucagon as a target for the treatment of type 2 diabetes. Exp. Opin. Ther. Targets 9, 593-600 (2005).
131. Agius, L. New hepatic targets for glycaemic control in diabetes. Best Pract. Res. Clin. Endocrinol. Metab. 21, 587-605 (2007).
132. Brand, C. L. et al. Immunoneutralization of endogenous glucagon with monoclonal glucagon antibody normalizes hyperglycaemia in moderately streptozotocin-diabetic rats. Diabetologia 37, 985-993 (1994).
133. Ling, A. et al. Human glucagon receptor antagonists based on alkylidene hydrazides. Bioorg. Med. Chem. Lett. 12, 663-666 (2002).
134. Winzell, M. S. et al. Glucagon receptor antagonism improves islet function in mice with insulin re sistance induced by a high-fat diet. Diabetologia 50, 1453-1462 (2007).
135. Filipsson, K. et al. The neuropeptide pituitary adenylate cyclase-activating polypeptide and islet function. Diabetes 50 1959-1969 (2001).
136. Ahrén B. Role of pituitary adenylate cyclase activating polypeptide in the pancreatic endocrine system. Ann. NY Acad. Sci. 1144, 28-35 (2008).
137. Jamen, F. et al. PAC1 receptor-deficient mice display impaired insulinotropic response to glucose and reduced glucose tolerance. J. Clin. Invest. 105, 1307-1315 (2000).
138. Asnicar, M. A. et al. Vasoactive intestinal polypeptide/pituitary adenylate cyclase-activating peptide receptor 2 deficiency in mice results in growth retardation and increased basal meta bolic rate. Endocrinology 143, 3994-4006 (2002).
139. Yada, T. et al. Intraperitoneal PACAP administration decreases blood glucose in GK rats, and in normal and high-fat diet mice. Ann. NY Acad. Sci. 92, 259-263 (2000).
140. Pan, C. Q. et al. Engineering novel VPAC2-selective agonists with improved stability and glucose-lowering activity in vivo. J. Pharmacol. Exp. Ther. 320, 900-906 (2007).
141. Morton, G. & Schwartz, M. The NPY/AgRP neuron and energy homeostasis. Int. J. Obes. Relat. Metab. Disord. 25 (Suppl. 5), S56-S62 (2001).
142. Brain, S. D. & Cox, H. M. Neuropeptides and their receptors: Innovative science providing novel therapeutic targets, Br. J. Pharmacol. 147, S202-S211 (2006).
143. Ahrén, B. et al. Neuropeptides and the regulation of islet function. Diabetes 55 (Suppl. 2), S98-S107 (2006).
144. Cox, H. M. Neuropeptide Y receptors; antisecretory control of intestinal epithelial function. Auton. Neurosci. 133, 76-85 (2007).
145. Morgan, D. G. et al. Inhibition of glucose-stimulated insulin secretion by neuropeptide Y is mediated via the Y1 receptor and inhibition of adenylyl cyclase in RIN 5AH rat insulinoma cells. Diabetologia 41, 1482-1491 (1998).
146. Skoglund, G. et al. Different mechanisms are in volved in neuropeptide Y-induced pancreatic vasoconstriction and inhibition of insulin secre tion. Eur. J. Pharmacol. 236, 69-74 (1993).
147. Cho, Y. R. & Kim, C. W. Neuropeptide Y promotes β-cell replication via extracellular signal-regulated kinase activation. Biochem. Biophys. Res. Commun. 314, 773-780 (2004).
148. Hartman, M.L. et al. Normal control of growth hormone secretion. Horm. Res. 40, 37-47 (1993).
149. Kojima, M. et al. Ghrelin: Discovery of the natural endogenous ligand for the growth hormone secretagogue receptor. Trends Endocrinol. Metab. 12, 118-126 (2001).
150. Kojima, M. et al. Ghrelin is a growth-hormone-releasing peptide from stomach. Nature 402, 656-660 (1999).
151. Kageyama, H. et al. Morphological analysis of ghrelin and its receptor distribution in the rat pancreas. Regul. Pept. 126, 67-71 (2005).
152. Dezaki, K. et al. Ghrelin is a physiological regulator of insulin release in pancreatic islets and glucose homeostasis. Pharmacol. Ther. 118, 239-249 (2008).
153. Ariyasu, H. et al. Stomach is a major source of circulating ghrelin, and feeding state determines plasma ghrelin-like immunoreactivity in humans. J. Clin. Endocrinol. Metab. 86, 4753-4758 (2001).
154. Volante, M. et al. Expression of ghrelin and of the GH secretagogue recepgor by pancreatic islet cells and related endocrine tumors. J. Clin. Endocrinol. Metab. 87, 1300-1308 (2002).
155. Date, Y. et al. Ghrelin is present in pancreatic α-cells of humans and rats and stimulates insulin secretion. Diabetes 51 124-129 (2002).
156. Wierup, N. et al. The ghrelin cell: A novel developmentally regulated islet cell in the human pancreas. Regul. Pept. 107 63-69 (2002).
157. Chanoine, J. P. & Wong, A. C. Ghrelin gene expression is markedly higher in fetal pancreas compared with fetal stomach: Effect of maternal fasting. Endocrinology 145, 3813-3820 (2004).
158. Reimer Kvist, M. et al. Dose-dependent inhibition by ghrelin of insulin secretion in the mouse. Endocrinology 144, 916-921 (2003).
159. Dezaki, K. et al. Blockade of pancreatic islet-derived ghrelin enhances insulin secretion to prevent high-fat diet-induced glucose tolerance. Diabetes 55, 3486-3493 (2006).
160. Sun, Y. et al. Ablation of ghrelin improves the diabetic but not obese phenotype of ob/ob mice. Cell Metab. 3, 379-386 (2006).
161. Esler, W. P. et al. Small-molecule ghrelin receptor antagonists improve glucose tolerance, suppress appetite, and promote weight loss. Endocrinology 148, 5175-5185 (2007).
162. Kotani, M. et al. The metastasis suppressor gene KiSS-1 encodes kisspeptins, the natural ligands of the orphan G protein-coupled receptor GPR54. J. Biol. Chem. 276, 34631-34636 (2001).
163. Hauge-Evans, A. C. et al. A role for kisspeptin in islet function. Diabetologia 49, 2131-2135 (2006).
164. Silvestre, R. A. et al. Kisspeptin-13 inhibits insulin secretion without affecting glucagon or somatostatin release: Study in the perfused rat pancreas. J. Endocrinol. 196, 283-290 (2008).
165. Karlsson, S. & Ahrén, B. Cholecystokinin and the regulation of insulin secretion. Scand. J. Gastroenterol. 27, 161-165 (1992).
166. Ahrén, B. et al. Neuropeptidergic versus cholinergic and adrenergic regulation of islet hormone secretion. Diabetologia 29, 827-836 (1986).
167. Ahrén, B. et al. Antidiabetogenic action of cholecystokinin-8 in type 2 diabetes. J. Clin. Endocrinol. Metab. 85, 1043-1048 (2000).
168. Peterhoff, M. et al. Inhibition of in sulin secretion via distinct signaling pathways in α2-adrenoceptor knockout mice. Eur. J. Endocrinol. 149, 343-350 (2003).
169. Natail A. et al. Effects of acute α2-blockade on insulin action and secretion in humans. Am. J. Physiol. 274, E57-E64 (1998).
170. Broadstone, V. L. et al. α-Adrenergic blockade improves glucose-potentiated insulin secretion in non-insulin-dependent diabetes mellitus. Diabetes 36, 932-937 (1987).
171. Peschke, E. Melatonin, endocrine pancreas and diabetes. J. Pineal Res. 44, 26-40 (2008).
172. Peschke, E. et al. Influence of melatonin and serotonin on glucose-stimulated insuilin release from perifused rat pancreatic islets in vitro. J. Pineal Res. 23, 156-163 (1997).
173. Kemp, D. M. et al. Identification and functional characterization of melatonin Mel 1a receptors in pancreatic β cells: Potential role in incretin-mediated cell function by sensitization of cAMP signaling. Mol. Cell. Endocrinol. 191, 157-166 (2002).
174. Picinato, M. C. et al. Melatonin inhibits insulin secretion and decreases PKA levels without interfering with glucose metabolism in rat pancreatic islets. J. Pineal Res. 33, 156-160 (2002).
175. Boden, G. et al. Evidence for a circadian rhythm of insulin secretion. Am. J. Physiol. 271, E246-E252 (1996).
176. Muhlbauer, E. & Peschke, E. Evidence for expression of both the MT1- and in addition, the MT2-melatonin receptor in the rat pancreas, islet and β-cell. J. Pineal Res. 42, 105-106 (2007).
177. Peschke, E. et al. Melatonin and type 2 diabetes - a possible link? J. Pineal Res. 42, 350-358 (2007).
178. Lyssenko, V. et al. Common variant in MTNR1B associated with increased risk of type 2 diabetes and impaired early insulin secretion. Nature Genet. 41, 82-88 (2009).
179. Prokopenko, I. et al. Variants in MTNR1B influence fasting glucose levels. Nature Genet. 41, 77-81 (2009).
180. Bouatia-Naji, N. et al. A variant near MTNR1B is associated with increased fasting plasma glucose levels and type 2 diabetes risk. Nature Genet. 41, 89-94 (2009).
181. Gautam, D. et al. A critical role for β cell M3 muscarinic acetylcholine receptors in regulating insulin release and blood homeostasis in vivo. Cell Metab. 3, 449-461 (2006).
182. Gautam, D. Role of M3 muscarinic acetylcholine receptor in β-cell function and glucose homeostasis, Diabet. Obes. Metab. 9 (Suppl. 2), 158-169 (2007).
183. Wess, J. et al. Muscarinic acetytlcholine receptors: Mutant mice provide new insights for drug development. Nature Rev. Drug Discov. 6, 721-733 (2007).
184. Ahrén, B. et al. Increased insulin secretion and normalisation of glucose tolerance by cholinergic agonist in fed C57BL/6J mice. Am. J. Physiol. 277, E93-E102 (1999).
185. Di Marzo, V. The endocannabinoid system in obesity and type 2 diabetes. Diabetologia 51, 1356-1367 (2008).
186. Xie, S. et al. The endocannabinoid system and rimonabant: A new drug with a novel mechanism of action involving cannabinoid CB1 receptor antagonism - or inverse agonism - as potential obesity treatment and other therapeutic use. J. Clin. Pharm. Ther. 32, 209-231 (2007).
187. 2+ signals and insulin secretion in pancreatic β-cells. Cell Calcium 39 155-162 (2006).
188. Starowicz, K. M. et al. Endocannabinoid dysregulation in the pancreas and adipose tissue of mice fed with a high-fat diet. Obesity 16, 553-565 (2008).
189. 2+ oscillation in islet β-cells via CB1 receptors. Regul. Pept. 145, 49-53 (2008).
190. Bermudez-Silva, F. J. et al., Presence of functional cannabinoid receptors in human endocrine pancreas. Diabetologia 51, 476-487 (2008).
191. Bermudez-Silva, F. J. et al. Activation of cannabinoid CB1 receptors induces glucose intolerance in rats. Eur. J. Pharmacol. 531, 282-284 (2006).
192. Scheen, A. J. et al. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: A randomized controlled study. Lancet 367, 1660-1672 (2006).
193. Christensen, R. et al. Efficacy and safety of the weight-loss drug rimonabant: A meta-analysis of randomised trials. Lancet 370 1706-1713 (2007).
194. Hillaire-Buys, D. et al. Purinergic receptors on insulin-secreting cells. Fundam. Clin. Pharmacol. 8, 117-127 (1994).
195. Chevassus, H. et al. P2Y receptor activation enhances insulin release from pancreatic β-cells by triggering the cyclic AMP/protein kinase A pathway. Naunyn Schmiedebergs Arch. Pharmacol. 366, 464-469 (2002).
196. Lugo-Garcia, L. et al. Expres sion of purinergic P2Y receptor
197. Parandeh F. et al. Uridine diphosphate (UDP) stimulates insulin secretion by activation of P2Y6 receptors. Biochem. Biophys. Res. Commun. 370, 499-503 (2008).
198. Williams, M. & Jarvis, M. F. Purinergic and pyrimidergic receptors as potential drug targets. Biochem. Pharmacol. 59, 1173-1185 (2000).
199. Novak, I. Purinergic receptors in the endocrine and exocrine pancreas. Purinergic Signal. 4, 237-253 (2008).
200. Fischer, B. et al. 2-thioether 5′-O-(1-thiotriphosphate) adenosine derivatives as new insulin secre tagogues acting through P2Y receptors. J. Med. Chem. 42, 3636-3646 (1999).
201. McKee, KK. et al. Cloning and characterization of two human G-protein-coupled receptor genes (GPR38 and GPR39) related to the growth hormone secretagogue and neurotensin receptors. Genomics 46, 426-434 (1997).
202. Zhang, J. V. et al. Obestatin, a peptide encoded by the ghrelin gene, opposes ghrelin's effect on food intake. Science 310, 996-999 (2005).
203. Dong, X. Y. et al. Is GPR39 the natural receptor of obestatin? Peptides 30, 431-438 (2009).
204. Holst, B. et al. GPR39 signaling is stimulated by zinc ions but not by obestatin. Endocrinology 48, 13-20 (2007).
205. Moerchans, D. et al. Altered gastrointestinal and metabolic function in the GPR39-obestatin receptor knockout mice. Gastroenterology 13, 1131-1141 (2006).
206. Chia, C. W. & Egan, J. M. Incretin-based therapies in type 2 diabetes mellitus. J. Clin. Endocrinol. Metab. 93, 3703-3716 (2008).
207. Ahrén B. Novel combination treatment of type 2 diabetes. DPP-4 inhibiton + metformin. Vasc. Health Risk. Management 4, 383-394 (2008).
208. de Heer, J. & Holst, J. J. Sulfonylurea compounds uncouple the glucose dependence of the insulinotropic effect of glucagon-like peptide 1. Diabetes 56, 438-434 (2007).
209. Filipsson, K. et al. Pituitary adenylate cyclase-activating polypeptide stimulates insulin and glucagon secretion in humans. J. Clin. Endocrinol. Metab. 82, 3093-3098 (1997).
210. 2+ transfer in the control of apoptosis. Oncogene 27, 6407-6418 (2008).
211. Imai, Y. et al. Analysis of gene expression in pancreatic islets from diet-induced obese mice. Physiol. Genomics 36, 43-51 (2008).
212. Simonsson, E. & Ahrén, B. Potentiated β-cell response to non-glucose stimuli in insulin resistant C57BL/6J mice. Eur. J. Pharmacol. 350, 243-250 (1998).
213. Flodgren, E. et al. Expression and function of GPR40 in Goto-Kakizaki rat islets. Diabetologia 49 (Suppl. 1), 316 (2006).
214. Malaisse, W. J. & Lebrun, P. Iterative stimulation of pancreatic islets by glipizide. Pharmacology 46, 43-49 (1993).
215. Gedulin, B. R. et al. Dose-response for glycaemic and metabolic changes 28 days after single injection of long-acting release exenatide in diabetic fatty Zucker rats. Diabetologia 48, 1380-1385 (2005).
216. Milligan, G. & Smith, N. J. Allosteric modulation of heterodimetic G-protein-coupled receptors. Trends Pharmacol. Sci. 28, 615-620 (2007).
217. Xiao, S. H. et al. High throughput screening for orphan and liganded GPCRs. Comb. Chem. High Throughput Screen. 11, 195-215 (2008).
218. Gloriam, D. E., Frederiksson, R. & Schiöth, H. B. The G-protein-coupled receptor subset of the rat genome. BMC Genomics 8, 338-405 (2007).
219. Civelli, O. GPCR deorphanizations: The novel, the known and the unexpected transmitters. Trends Pharmacol. Sci. 26, 15-19 (2005).
220. Foord, S. M. et al. G-protein coupled receptor list. Pharmacol. Rev. 57, 279-288 (2005).
221. Wess, J. G-protein-coupled receptors: Molecular mechanisms involved in receptor activation and selectivity of G-protein recognition. FASEB J. 11, 346-354 (2007).
222. Yeagle, P. L. & Albert, A. D. G-protein coupled receptor structure. Biochim. Biophys. Acta 1768, 808-824 (2007).
223. Neves, S. R., Ram, P. T. & Iyengar, R. G protein pathways. Science 296, 1636-1639 (2002).
224. Holst, J. J. The physiology of glucagon-like peptide-1. Physiol. Rev. 87, 1409-1439 (2007).
225. Flatt, P. R. Gastric inhibitory polypeptide (GIP) revisited: A new therapeutic target for obesitydiabetes? Diabet. Med. 25, 759-764 (2008).
226. Swaminath, G. Fatty acid binding receptors and their physiological role in type 2 diabetes. Arch. Pharm. 341, 753-761 (2008).
227. Hirasawa, A. et al. Free fatty acid receptors and drug discovery. Biol. Pharm. Bull. 31, 1847-1851 (2008).
228. Brown, A. J. et al. A family of fatty acid binding receptors. DNA Cell Biol. 24, 54-61 (2005).
229. Laburthe, M. et al. Class II G protein-coupled receptors for VIP and PACAP: Structure, models of activation and pharmacology. Peptides 28, 1631-1639 (2007).
230. Mead, E. J. et al., Kisspeptins: A multifunctional peptide system with a role in reproduction, cancer and the cardiovascular system. Br. J. Pharmacol. 151, 1143-1153 (2007).
231. Berna, M. J. et al. Progress in developing cholecystokinin (CCK)/ gastrin receptor ligands that have therapeutic potential. Curr. Opin. Pharmacol. 7, 583-592 (2007).
232. McGraw, D. W. & Ligget, S. B. Molecular mechanisms of β2-adrenergic receptor function and regulation. Proc. Am. Thorac. Soc. 2, 292-296 (2005).
233. Gentili, F. et al. Agonists and antagonists targeting the different α2-adrenoceptor subtypes. Curr. Top. Med. Chem. 7 163-186 (2007).
234. Jockers, R. et al. Melatonin receptors, heterodimerization, signal transduction and binding sites: What's new? Br. J. Pharmacol. 154, 1182-1195 (2008).
235. Gautam, D. et al. Metabolic roles of the M3 muscarinic acetylcholine receptor studies with M3 receptor mutant mice: A review. J. Recept. Signal Transduct. Res. 28, 93-108 (2008).
236. Russell-Jones D. Molecular, pharmacological and clinical aspects of liraglutide, a once-daily human GLP1 analogue. Mol. Cell. Endocrinol. 297, 137-140 (2009).